SK Biopharmaceuticals Co., Ltd.

Equities

A326030

KR7326030004

Pharmaceuticals

End-of-day quote Korea S.E. 23:00:00 11/07/2024 BST 5-day change 1st Jan Change
83,000 KRW +3.36% Intraday chart for SK Biopharmaceuticals Co., Ltd. +5.06% -17.33%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
SK Biopharmaceuticals Turns to Profit in Q1 as Sales Jump 88% MT
SK Biopharmaceuticals Swings to Profit in Q4 MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal MT
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CI
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference CI
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd.. CI
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2% MT
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division MT
SK Biopharmaceuticals Continues to Report Losses in Q2 MT
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation CI
SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029 MT
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million. CI
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
SK Biopharmaceuticals Narrows Loss in Q1 MT
SK Biopharmaceuticals Swings to Loss in Q4 MT
SK Biopharmaceuticals' Anti-Epilepsy Treatment Cenobamate Approve for Sale in France MT
SK Biopharmaceuticals Co. Ltd Partner Angelini Pharma Launches Cenobamate in France CI
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device At AES 2022 CI
SK Biopharmaceuticals Appoints Donghoon Lee as President of Company and U.S. Subsidiary Effective January 1, 2023 CI
SK Biopharmaceuticals and SK Life Science Announces Executive Changes CI
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969 CI
SK Biopharmaceuticals, Co., Ltd., Eurofarma Enters into Licensing Agreement for Cenobamate in Latin America CI
SK Biopharmaceuticals Swings to Loss in Q1 MT
Axsome Therapeutics to Buy Sunosi From Jazz Pharmaceuticals DJ
BIORCHESTRA and SK Biopharmaceuticals Collaborate to Develop Mirna-Targeted Therapeutics CI
Chart SK Biopharmaceuticals Co., Ltd.
More charts
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
83,000 KRW
Average target price
107,438 KRW
Spread / Average Target
+29.44%
Consensus
  1. Stock Market
  2. Equities
  3. A326030 Stock
  4. News SK Biopharmaceuticals Co., Ltd.
  5. SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029